BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient

Rhea-AI Summary

BriaCell (Nasdaq: BCTX) reported an 11-month sustained complete resolution of a lung metastasis in the first patient enrolled in the Bria-OTS Phase 1/2a metastatic breast cancer study.

The 78-year-old hormone receptor-positive, HER2-negative patient achieved 100% resolution after four doses of Bria-OTS monotherapy, with the response first seen at 2 months and confirmed at 4, 6, and 11 months; the patient completed 12 months on study, received 17 cycles, reported no treatment-limiting toxicities, maintained stable disease at other evaluable sites, and remains in survival follow-up.

The Phase 1 dose-escalation is complete and the Phase 2a combination study with an immune checkpoint inhibitor is underway.

Positive

• 100% resolution of a lung metastasis confirmed at 2, 4, 6, and 11 months
• Patient completed 17 cycles and 12 months on study
• No treatment-limiting toxicities reported
• Phase 1 dose escalation complete; Phase 2a combination study underway

Negative

• Efficacy reported in a single patient, limiting generalizability

News Market Reaction

+42.93% 96.5x vol

20 alerts

+42.93% News Effect

+120.0% Peak Tracked

-45.3% Trough Tracked

+$6M Valuation Impact

$21M Market Cap

96.5x Rel. Volume

On the day this news was published, BCTX gained 42.93%, reflecting a significant positive market reaction. Argus tracked a peak move of +120.0% during that session. Argus tracked a trough of -45.3% from its starting point during tracking. Our momentum scanner triggered 20 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $6M to the company's valuation, bringing the market cap to $21M at that time. Trading volume was exceptionally heavy at 96.5x the daily average, suggesting very strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Sustained response duration: 11 months Patient age: 78 years Bria-OTS doses: 4 doses +4 more

7 metrics

Sustained response duration 11 months Complete resolution of lung metastasis in Bria-OTS Phase 1/2a patient

Patient age 78 years First Bria-OTS metastatic breast cancer patient

Bria-OTS doses 4 doses Single-agent therapy before complete lung metastasis resolution

Tumor response 100% resolution Lung metastasis in metastatic breast cancer patient

Follow-up confirmations 2, 4, 6, 11 months Timepoints confirming complete lung metastasis resolution

Bria-OTS cycles 17 cycles Total cycles received; patient completed 12 months on study

Study phase Phase 1/2a Metastatic breast cancer study of Bria-OTS

Market Reality Check

Price: $4.29 Vol: Volume 73,248 is close to...

normal vol

$4.29 Last Close

Volume Volume 73,248 is close to the 20-day average of 76,675 (relative volume 0.96). normal

Technical Shares at $7.64 are trading below the 200-day MA of $18.88 and far below the 52-week high of $98.20.

Peers on Argus

BCTX gained 5.38% while several peers declined (ADAP -17.57%, CYCC -5.84%, PRTG ...

BCTX gained 5.38% while several peers declined (ADAP -17.57%, CYCC -5.84%, PRTG -10.39%, IMNN -4.04%), indicating a stock-specific move rather than a sector-wide rally.

Historical Context

5 past events · Latest: Dec 18 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 18	Phase 3 spotlight	Positive	+3.2%	Phase 3 Bria-IMT trial featured among key 2026-shaping studies.
Dec 10	Clinical data update	Positive	-7.9%	Presented Phase 2 survival and Phase 3 biomarker data at SABCS 2025.
Dec 09	Enrollment progress	Positive	-2.1%	Reported strong Phase 3 enrollment and plans for interim OS analysis.
Dec 02	SABCS preview	Positive	+3.7%	Announced upcoming SABCS posters with positive Phase 2 and Phase 3 data.
Nov 25	Data highlight	Positive	+13.5%	Planned SABCS 2025 presentations of positive Phase 2 and Phase 3 results.

Pattern Detected

Recent positive clinical updates have produced mixed reactions, with three news events leading to gains and two to selloffs, suggesting inconsistent alignment between upbeat trial news and short-term price moves.

Recent Company History

Over the last two months, BriaCell has repeatedly highlighted progress in its metastatic breast cancer programs, including Phase 3 enrollment milestones, positive Phase 2 survival signals, and recognition in Nature Medicine’s list of trials that may shape 2026. Price reactions to these largely positive clinical updates have varied, with both notable gains (up to 13.53%) and declines after similar news. Today’s Bria-OTS complete lung metastasis resolution update adds another positive clinical data point to this evolving story.

Market Pulse Summary

The stock surged +42.9% in the session following this news. A strong positive reaction aligns with t...

Analysis

The stock surged +42.9% in the session following this news. A strong positive reaction aligns with the favorable Bria-OTS clinical update, where a patient achieved a 100% lung metastasis resolution sustained for 11 months. Historically, BriaCell’s positive trial news has produced mixed short-term moves, with several recent clinical milestones leading to both gains and declines. The stock remained far below its $98.20 52-week high and below the $18.88 200-day MA, so traders may have focused on upside potential against a depressed longer-term backdrop.

Key Terms

metastatic breast cancer, hormone receptor-positive, her2-negative, immune checkpoint inhibitor, +3 more

7 terms

metastatic breast cancer medical

"Bria-OTS Phase 1/2a metastatic breast cancer study."

Metastatic breast cancer is breast cancer that has spread beyond the breast and nearby lymph nodes to other organs, such as bones, liver, lungs or brain. For investors it matters because these advanced-stage cases often require long-term, complex and costly treatments, drive demand for specialty drugs and diagnostics, and influence regulatory approvals, pricing negotiations and the long-term revenue potential of companies developing therapies aimed at slowing spread or improving quality of life. An everyday analogy: it’s like a weed that has taken root in multiple beds rather than just one garden patch, requiring broader and more sustained effort to manage.

hormone receptor-positive medical

"The patient is hormone receptor-positive (HR+), HER2-negative."

A tumor described as hormone receptor-positive has cancer cells that carry proteins on their surface which hormones — most commonly estrogen or progesterone — can bind to and use like a key to stimulate growth. For investors this matters because it determines whether hormone-blocking drugs and specific diagnostic tests are likely to work, shaping treatment options, market demand, clinical trial strategies and the commercial outlook for related therapies.

her2-negative medical

"The patient is hormone receptor-positive (HR+), HER2-negative."

HER2-negative describes a cancer that does not have an excess of the HER2 protein on tumor cells; think of it as a door that lacks a specific lock that certain drugs are designed to fit. It matters to investors because it determines which therapies can work, how large the treatable patient group is, and the commercial and clinical prospects for drugs and trials targeting that subtype.

immune checkpoint inhibitor medical

"Phase 2a portion, evaluating combination of Bria-OTS with an immune checkpoint inhibitor,"

An immune checkpoint inhibitor is a type of medicine that helps the body's immune system recognize and attack cancer cells more effectively. It works by blocking certain signals that cancer uses to hide from immune defenses, allowing the immune system to target tumors. This breakthrough has led to new cancer treatments, making immune checkpoint inhibitors an important area of growth and innovation in the healthcare industry.

monotherapy medical

"Treatment with Bria-OTS monotherapy resulted in 100% resolution of tumor"

Monotherapy is a treatment approach that uses only one type of medicine or therapy to address a condition, instead of combining multiple options. For investors, understanding monotherapy matters because it can influence a company's development strategy, risk profile, and potential market size, especially if the single-treatment approach proves effective or faces limitations compared to combination therapies.

phase 1 medical

"The Phase 1 dose escalation portion of the study is complete"

Phase 1 is the first stage of testing a new drug or medical treatment in people, focused primarily on safety, how the body handles the product, and finding a tolerated dose. Think of it as a short, tightly controlled experiment with a small group to check for dangerous side effects before wider testing; for investors it is an early milestone that reduces some uncertainty but still carries high risk and potential for both big value changes and setbacks.

phase 2a medical

"The Phase 1 dose escalation portion of the study is complete and the Phase 2a portion,"

Phase 2a is an early stage in testing a new medical treatment or drug, where the main goal is to assess its safety and find the right dosage. For investors, this stage indicates whether the treatment shows initial promise before moving on to larger, more definitive studies; progress here can influence expectations for future development and potential success.

AI-generated analysis. Not financial advice.

• [IMAGES BELOW] 11-month sustained complete resolution of lung metastasis observed in Bria-OTS Phase 1/2a metastatic breast cancer study.
  
• No treatment limiting toxicities reported.
  
• Patient maintained stable disease at all other evaluable sites.
  

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 13, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announces the durable and sustained complete resolution of a lung metastasis in a patient with metastatic breast cancer (MBC) treated with Bria-OTS, BriaCell’s personalized off the shelf immunotherapy. The patient is hormone receptor-positive (HR+), HER2-negative.

The first patient enrolled in the Bria-OTS study, a 78-year-old woman with advanced metastatic breast cancer and multiple prior treatment failures, achieved complete (100%) resolution of a lung metastasis following four doses of Bria-OTS single agent therapy. The complete response, initially observed at 2 months (previously reported), was subsequently confirmed at 4 months (previously reported), 6 months (previously reported), and now at 11 months. The patient received 17 cycles of Bria-OTS, completed 12 months of the study, and remains in survival follow-up. 

Figure 1: Treatment with Bria-OTS monotherapy resulted in 100% resolution of tumor in the right lung of the metastatic breast cancer (MBC) patient following 2 months of therapy and confirmed at 4, 6, and 11 months of therapy¹ (axial and coronal views)

The Phase 1 dose escalation portion of the study is complete and the Phase 2a portion, evaluating combination of Bria-OTS with an immune checkpoint inhibitor, is now underway.

“The sustained clinical response observed in this late-stage MBC patient, who had previously progressed through multiple prior treatments is remarkable,” stated Neal S. Chawla MD, Director at the Sarcoma Oncology Center, Santa Monica, CA, and Principal Investigator for the Bria-OTS study. “We are excited to further evaluate Bria-OTS in combination with an immune checkpoint inhibitor in metastatic breast cancer.”

“These clinical findings reinforce our confidence in the therapeutic potential and safety of the Bria-OTS platform,” added Dr. William V. Williams, BriaCell’s President and CEO. “Our team remains committed to advancing our novel therapeutic approach with the goal of making a meaningful difference for patients with metastatic breast cancer, particularly those with limited treatment options.”

About Bria-OTS

Bria-OTS is a next generation, off-the-shelf personalized immunotherapy based on BriaCell’s lead candidate Bria-IMT currently being evaluated in a Phase 1/2a study (ClinicalTrials.gov identifier: NCT06471673) in patients with metastatic recurrent breast cancer. The trial includes both monotherapy dose escalation and checkpoint inhibitor combination dose expansion cohorts. The Company has recently entered the dose expansion phase.

About BriaCell Therapeutics Corp.

BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/.

Safe Harbor

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release include statements regarding: BriaCell continuing the Phase 1/2a Bria-OTS study and reproducing similar results in patients with MBC and other cancers; the use of the Bria-OTS platform as monotherapy; and Bria-OTS’s validation as a personalized immunotherapy approach. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company’s most recent Management’s Discussion and Analysis, under the heading “Risk Factors” in the Company’s most recent Annual Information Form, and under “Risks and Uncertainties” in the Company’s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company’s profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.

Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com 

Investor Relations Contact:
investors@briacell.com

¹ Note that the other white dots in the lungs are blood vessels.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/be299ddd-4e02-4bf0-8b5a-f704f172076e

FAQ

What did BriaCell announce about the Bria-OTS result on January 13, 2026 for BCTX?

BriaCell reported an 11-month sustained complete resolution of a lung metastasis in the first Bria-OTS patient, confirmed at 2, 4, 6, and 11 months.

Which patient type showed the complete response in the Bria-OTS study (BCTX)?

A 78-year-old woman with hormone receptor-positive, HER2-negative metastatic breast cancer who had multiple prior treatment failures.

Did the Bria-OTS patient experience serious safety issues in the BCTX report?

No treatment-limiting toxicities were reported for the patient in the announcement.

How many cycles and months did the Bria-OTS responder receive in the BCTX study?

The patient received 17 cycles and completed 12 months on study and remains in survival follow-up.

What is the next clinical step for Bria-OTS reported by BriaCell (BCTX)?

The Phase 1 dose-escalation is complete and the Phase 2a study evaluating Bria-OTS combined with an immune checkpoint inhibitor is now underway.